Most Read Articles
Elaine Soliven, 16 Oct 2018
The use of degludec in insulin-naïve patients with type 2 diabetes (T2D) appears to reduce HbA1c levels with a lower risk of hypoglycaemia, based on real-world data from the CONFIRM* trial presented at EASD 2018.
Pearl Toh, 2 days ago
Zoledronate significantly reduces the risk of both nonvertebral and vertebral fragility fractures over 6 years in older women with osteopenia — a substantial patient group at risk for fractures but in whom a knowledge gap remains for pharmacological treatment, reveals a large randomized trial.
21 Jul 2018
Use of statins may contribute to an increased risk of developing gynecomastia, as shown in a study.
Pank Jit Sin, 18 Apr 2016

With diabetes being one of the country’s biggest health issues, local experts welcome any help in their battle against the disease. 

Minimal extrathyroid extension ups recurrence risk in differentiated thyroid cancer

10 Jul 2018

The risk of recurrence for differentiated thyroid cancer (DTC) escalates in patients with minimal extrathyroid extension (mETE), but the absolute increase in risk is small, according to a recent study.

Additionally, the risk is within the low-risk of recurrence category at 3.5 percent in patients without lymph node involvement (N0 disease). mETE confers no effect on disease-related mortality and should not change tumour stage.

The authors performed a meta-analysis of controlled trials comparing DTC patients with and without mETE to examine the impact of mETE on patient outcomes. A total of 13 retrospective studies including 23,816 patients met the inclusion criteria, with a median follow-up of 86 months.

In patients with N0 disease, mETE correlated with increased risk of recurrence (seven studies: odds ratio [OR], 1.73; 95 percent CI, 1.03–2.92). The absolute risk of recurrence was 2.2 percent and 3.5 percent in patients without and with mETE, respectively (p=0.04).

Studies involving patients with and without lymph node involvement showed mETE to be associated with a significantly higher risk of recurrence (eight studies: OR, 1.82; 1.14–2.91). The absolute risk of recurrence was 6.2 percent and 7 percent in patients without and with mETE, respectively (p=0.01).

mETE had nonsignificant impact (OR, 2.40; 0.95–6.03) in patients with micropapillary carcinoma, while no impact was seen on disease-related mortality (eight studies: OR, 0.5; 0.11–2.21).

“mETE in patients with DTC was defined as an intermediate risk feature in the 2015 American Thyroid Association guidelines. However, controversy persists as several studies suggested mETE has little effect on disease outcome,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 16 Oct 2018
The use of degludec in insulin-naïve patients with type 2 diabetes (T2D) appears to reduce HbA1c levels with a lower risk of hypoglycaemia, based on real-world data from the CONFIRM* trial presented at EASD 2018.
Pearl Toh, 2 days ago
Zoledronate significantly reduces the risk of both nonvertebral and vertebral fragility fractures over 6 years in older women with osteopenia — a substantial patient group at risk for fractures but in whom a knowledge gap remains for pharmacological treatment, reveals a large randomized trial.
21 Jul 2018
Use of statins may contribute to an increased risk of developing gynecomastia, as shown in a study.
Pank Jit Sin, 18 Apr 2016

With diabetes being one of the country’s biggest health issues, local experts welcome any help in their battle against the disease.